Literature DB >> 32279414

Guidance on the diagnosis and management of platelet-type von Willebrand disease: A communication from the Platelet Physiology Subcommittee of the ISTH.

Maha Othman1,2, Paolo Gresele3.   

Abstract

Platelet-type von Willebrand disease (PT-VWD) is a rare autosomal dominant platelet bleeding disorder, with 55 patients reported worldwide so far, probably frequently misdiagnosed. Currently, there are no clear guidelines for the diagnosis and management of PT-VWD and this may contribute to misdiagnosis and thus to inappropriate treatment of these patients. This report provides expert opinion-based consensus recommendations for the standardized diagnostic and management approach to PT-VWD. Tests essential in the diagnostic workup are platelet count and size, ristocetin-induced platelet agglutination with mixing studies, and sequencing of platelet GP1BA gene. Platelet transfusions and von Willebrand factor-rich concentrates (if VWF is low) are the most effective treatments. This consensus may help to avoid misdiagnosis and guide appropriate management of patients with this disease.
© 2020 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  GPIb alpha; PT-VWD; macrothrombocytopenia; platelet dysfunction; thrombocytopenia

Mesh:

Substances:

Year:  2020        PMID: 32279414     DOI: 10.1111/jth.14827

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  6 in total

1.  ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease.

Authors:  Nathan T Connell; Veronica H Flood; Romina Brignardello-Petersen; Rezan Abdul-Kadir; Alice Arapshian; Susie Couper; Jean M Grow; Peter Kouides; Michael Laffan; Michelle Lavin; Frank W G Leebeek; Sarah H O'Brien; Margareth C Ozelo; Alberto Tosetto; Angela C Weyand; Paula D James; Mohamad A Kalot; Nedaa Husainat; Reem A Mustafa
Journal:  Blood Adv       Date:  2021-01-12

2.  ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease.

Authors:  Paula D James; Nathan T Connell; Barbara Ameer; Jorge Di Paola; Jeroen Eikenboom; Nicolas Giraud; Sandra Haberichter; Vicki Jacobs-Pratt; Barbara Konkle; Claire McLintock; Simon McRae; Robert R Montgomery; James S O'Donnell; Nikole Scappe; Robert Sidonio; Veronica H Flood; Nedaa Husainat; Mohamad A Kalot; Reem A Mustafa
Journal:  Blood Adv       Date:  2021-01-12

Review 3.  Inherited Platelet Disorders: An Updated Overview.

Authors:  Verónica Palma-Barqueros; Nuria Revilla; Ana Sánchez; Ana Zamora Cánovas; Agustín Rodriguez-Alén; Ana Marín-Quílez; José Ramón González-Porras; Vicente Vicente; María Luisa Lozano; José María Bastida; José Rivera
Journal:  Int J Mol Sci       Date:  2021-04-26       Impact factor: 5.923

4.  2B von Willebrand disease diagnosis: Considerations reflecting on 2021 multisociety guidelines.

Authors:  Maha Othman; Emmanuel J Favaloro
Journal:  Res Pract Thromb Haemost       Date:  2021-12-20

5.  A p.Arg127Gln variant in GPIbα LRR5 allosterically enhances affinity for VWF: a novel form of platelet-type VWD.

Authors:  Loredana Bury; Emanuela Falcinelli; Haripriya Kuchi Bhotla; Anna Maria Mezzasoma; Giuseppe Guglielmini; Alexander Tischer; Laurie Moon-Tasson; Matthew Auton; Paolo Gresele
Journal:  Blood Adv       Date:  2022-04-12

6.  GoldVariants, a resource for sharing rare genetic variants detected in bleeding, thrombotic, and platelet disorders: Communication from the ISTH SSC Subcommittee on Genomics in Thrombosis and Hemostasis.

Authors:  Karyn Megy; Kate Downes; Marie-Christine Morel-Kopp; José M Bastida; Shannon Brooks; Loredana Bury; Eva Leinoe; Keith Gomez; Neil V Morgan; Maha Othman; Willem H Ouwehand; Juliana Perez Botero; José Rivera; Harald Schulze; David-Alexandre Trégouët; Kathleen Freson
Journal:  J Thromb Haemost       Date:  2021-08-05       Impact factor: 16.036

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.